In vitro studies evaluated methods for testing the susceptibility of Haemophilus influenzae to piperacillintazobactam combinations. Ampicillin-resistant 1-lactamase-nonproducing strains of H. influenzae may be presumed to be relatively resistant to combinations of piperacillin-tazobactam, even though they frequently appear to be susceptible by disk diffusion methods. Other ampicillin-resistant or -susceptible strains were predictably susceptible; i.e., 130 such strains gave zones of inhibition .26 mm in diameter, and MICs for these strains were <0.125/4.0 p,g/ml (<1.0/0.12 ,ug/ml when an 8:1 ratio was tested 
against Haemophilus influenzae, but it is readily inactivated by the ,-lactamases that are produced by some strains. If a P-lactamase inhibitor were coadministered with piperacillin, it should be equally active against 3-lactamase-producing and -nonproducing strains. Tazobactam is the ,B-lactamase inhibitor that has been combined with piperacillin for clinical application. This combination is active against a broad range of bacterial species, including H. influenzae (3, 5) . Although piperacillin-tazobactam is not intended to be a primary drug for treating H. influenzae infections, it might be appropriate for treating mixed infections that include H. influenzae. confirmed before being reported. Although some strains are 1 contains scattergrams generated with the two types relatively resistant, they are not necessarily resistant cliniIs (8:1 ratios and constant concentrations of 4,ug/ml) cally. In practice, 3-lactamase-nonproducing strains (ampi-*ed with zone diameters around 100/10-,ug piperacil-cillin susceptible or resistant) would not be treated with any )bactam disks. The 41 3-lactamase-producing strains 1-lactamase inhibitor-13-lactam combination, and at this niformly susceptible to either piperacillin-tazobactam point, all P-lactamase-producing strains can be assumed to ation. When the two drugs were tested in an 8:1 be susceptible to the inhibitor combinations. Although not tation, P-lactamase-producers were inhibited by 0.12/ included in the present study, strains of H. influenzae that ) 1.0/0.12,g of piperacillin-tazobactam per ml. Of the produce an extended-spectrum ROB-1 1-lactamase have picillin-susceptible isolates, 88 were inhibited by been found by one of us (F.C.T.) to be susceptible to the ).008 ,ug/ml, and the MIC for one strain was 0.12/ drug combination. Continued surveillance is needed in order g/ml. When the amount of tazobactam was increased to detect any changes in microbial populations, and for that instant concentration of 4.0 ,ug/ml, ,B-lactamase-proreason, clinical microbiology laboratories might be asked to and -nonproducing strains were both inhibited by evaluate piperacillin-tazobactam against selected strains.
pug of piperacillin per ml. Tazobactam alone (4.0
Two different multilaboratory studies were undertaken in failed to inhibit any of the strains included in this order to evaluate the reproducibilities of disk diffusion and More than 99% of the zones of inhibition were .29 broth microdilution tests with the standard Ampr BLNP diameter (one outlying strain had a 26-mm-diameter control strain of H. influenzae (ATCC 49247). Each study involved tests with a different lot of agar or broth assigned to results of tests with Ampr BLNP strains were exameach of five participants and a sixth lot that was common to parately to determine whether the diminished suscepall participants. Each laboratory performed replicate tests, s of these strains could be identified by the two testing and the distribution of MICs or zone diameters was evaluures (microdilution and disk diffusion tests). In Fig. 1 , ated in order to define the range of acceptable results. The ults of tests with each Ampr BLNP strain are indioverall distribution of zone measurements around 100/10-,ug y open circles. All 19 strains produced large zones of piperacillin-tazobactam disks is displayed in Table 1 . Conon (31 to 40 mm in diameter). As might be expected, trol limits that accept zone diameters of 32 to 38 mm were licrodilution tests were not influenced by the amount calculated by using the median statistic of Gavan et al. (3) . bactam in the test system: with either combination, 
